These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21199574)

  • 1. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
    Bankstahl JP; Bankstahl M; Kuntner C; Stanek J; Wanek T; Meier M; Ding XQ; Müller M; Langer O; Löscher W
    J Neurosci; 2011 Jun; 31(24):8803-11. PubMed ID: 21677164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate.
    Syvänen S; Schenke M; van den Berg DJ; Voskuyl RA; de Lange EC
    AAPS J; 2012 Mar; 14(1):87-96. PubMed ID: 22215264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
    Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
    Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
    Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
    J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling.
    De Lange ECM; Vd Berg DJ; Bellanti F; Voskuyl RA; Syvänen S
    Eur J Pharm Sci; 2018 Nov; 124():61-70. PubMed ID: 30144528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET.
    Syvänen S; Labots M; Tagawa Y; Eriksson J; Windhorst AD; Lammertsma AA; de Lange EC; Voskuyl RA
    J Nucl Med; 2012 Dec; 53(12):1974-83. PubMed ID: 23143088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
    Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
    Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
    Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.
    Luurtsema G; Molthoff CF; Windhorst AD; Smit JW; Keizer H; Boellaard R; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2003 Oct; 30(7):747-51. PubMed ID: 14499333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.
    Bauer M; Zeitlinger M; Karch R; Matzneller P; Stanek J; Jäger W; Böhmdorfer M; Wadsak W; Mitterhauser M; Bankstahl JP; Löscher W; Koepp M; Kuntner C; Müller M; Langer O
    Clin Pharmacol Ther; 2012 Feb; 91(2):227-33. PubMed ID: 22166851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
    Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
    J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease.
    Bartels AL; de Klerk OL; Kortekaas R; de Vries JJ; Leenders KL
    Curr Top Med Chem; 2010; 10(17):1775-84. PubMed ID: 20645917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.